Summary: A nationwide, population-based cohort study using one of the world’s largest healthcare databases found a specific biological association between neovascular age-related macular degeneration (nAMD) and higher risks for certain cancers. Researchers followed 334,091 people aged 50 and older—83,742 with nAMD and 250,349 matched controls—over up to 10 years. The results show a selective pattern of cancer susceptibility rather than a broad increase in all malignancies.
Patients with nAMD faced significantly elevated risks for thyroid, kidney, pancreatic, lung, bladder, and prostate cancers. The study suggests that advanced retinal degeneration can reflect wider systemic vulnerabilities driven by a shared aging–inflammation–vasculature axis—an interplay of chronic inflammation, vascular dysfunction, cellular senescence, oxidative stress, and extracellular matrix remodeling.
Key Facts
- Large national cohort: Using the Korean National Health Insurance Service, investigators tracked more than 330,000 participants for up to a decade, providing robust statistical power to detect selective cancer associations.
- Selective cancer risk: nAMD was linked to higher risks for thyroid, renal (kidney), pancreatic, lung, bladder, and prostate cancers, while many other common cancers showed no statistical association.
- Strongest link — thyroid: Thyroid cancer showed one of the strongest associations; nAMD patients had about a 24% higher risk over the study period compared with matched controls.
- VEGF and limitations: Both nAMD and many tumors use VEGF-driven angiogenesis, but routine intraocular anti-VEGF therapy is localized and unlikely to explain systemic cancer risk fully.
- Shared biological axis: Authors propose an aging–inflammation–vasculature axis—encompassing chronic low-grade inflammation, immune dysregulation, cellular senescence, oxidative stress, and tissue remodeling—that may underlie both retinal degeneration and selective cancer vulnerability.
- Genetic overlap: Emerging genetic evidence points to overlapping polygenic risk affecting complement activation, lipid metabolism, and extracellular matrix regulation, which may predispose to both nAMD and some cancers.
- No immediate change to screening: The increased risks are modest and selective. The authors advise against specialized cancer screening solely because of an nAMD diagnosis; routine, age-appropriate screening remains the recommended approach.
Source: Impact Journals
Neovascular age-related macular degeneration (nAMD) is a leading cause of severe vision loss in older adults. Although the disorder is primarily ocular, it increasingly appears to reflect systemic aging processes—chronic inflammation, vascular dysfunction, and immune changes—that also play roles in cancer development. This raised the question of whether nAMD and certain cancers share common biological drivers.
To investigate, researchers analyzed records from the Korean National Health Insurance Service. The study followed 334,091 individuals aged 50 or older—83,742 with diagnosed nAMD and 250,349 matched controls—over as long as ten years to evaluate overall and site-specific cancer incidence.
Overall cancer risk was modestly but significantly higher among people with nAMD (adjusted hazard ratio [aHR], 1.084; P < 0.001). Importantly, this increase was not uniform across cancer types. Statistically significant, selective elevations were seen for pancreatic (aHR 1.155), lung (aHR 1.128), thyroid (aHR 1.241), renal (aHR 1.177), bladder (aHR 1.121), and prostate (aHR 1.085) cancers. No significant links were observed for many other malignancies.
The research team considered several biological explanations. Angiogenesis, driven by vascular endothelial growth factor (VEGF), contributes to both nAMD and tumor growth, but the routine anti-VEGF injections used to treat nAMD are delivered directly into the eye and remain largely localized, so they are unlikely to modify systemic cancer risk. Instead, investigators emphasize broader, systemic mechanisms—chronic inflammation, immune dysregulation, cellular senescence, oxidative stress, and matrix remodeling—as plausible shared drivers.
Genetic studies discussed in the paper add weight to the idea of overlap: genetic variants that influence complement activation, lipid handling, and extracellular matrix function can increase susceptibility to retinal degeneration and, independently, to tumor development. Together, these findings point to a complex, polygenic susceptibility that manifests in different tissues according to local microenvironments and exposures.
Clinically, the authors urge caution in interpreting these results. The associations are important for understanding systemic aging biology but are modest at the individual level. An nAMD diagnosis does not mandate intensified or off-guideline cancer screening. Instead, patients should continue routine, age-appropriate health checks and keep their primary care providers informed.
In summary, this large, nationwide cohort study suggests that nAMD may mark a selective vulnerability to certain cancers through shared angiogenic, inflammatory, and polygenic aging-related mechanisms. The findings reinforce the view that aging-related diseases often share biological pathways across organs and underscore the need for further research into how systemic aging processes contribute to both vision loss and cancer development.
Key Questions Answered:
A: No. The study reports a modest statistical association, not a direct cause-and-effect outcome. While nAMD may reflect systemic vulnerabilities that slightly increase risk for certain cancers, the absolute risk for any individual remains relatively small.
A: No. Authors caution against extra invasive screening based solely on nAMD. Follow standard, age-appropriate screening recommendations and discuss concerns with your primary care clinician.
A: Anti-VEGF treatment for macular degeneration is administered locally into the eye and produces minimal systemic exposure. The study suggests the shared link extends beyond VEGF to broader inflammatory and genetic mechanisms.
Editorial Notes:
- Article edited by a Neuroscience News editor.
- Journal paper reviewed in full; additional context added by staff.
About this cancer and visual neuroscience research news
Author: Ryan Braithwaite
Source: Impact Journals LLC
Contact: Ryan Braithwaite – Impact Journals LLC
Image: Image credit: Neuroscience News
Original Research: Open access. “Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study” by Hyeong Min Kim, Yoonjong Bae, Mina Kim, Hyungwoo Lee, and Hyewon Chung. DOI: 10.18632/aging.206383
Abstract
Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults and increasingly viewed as part of systemic aging involving vascular and inflammatory pathways. Using the Korean National Health Insurance Service, researchers conducted a nationwide cohort study including 334,091 individuals (83,742 with nAMD and 250,349 matched controls) followed up to 10 years.
Patients with nAMD had a modest but significant increase in overall cancer risk (adjusted hazard ratio [aHR] 1.084; P < 0.001), with selectively elevated risks for pancreatic (aHR 1.155), lung (aHR 1.128), thyroid (aHR 1.241), renal (aHR 1.177), bladder (aHR 1.121), and prostate (aHR 1.085) cancers. No associations were found for many other malignancies. These results suggest nAMD may act as a clinical marker of systemic vulnerability to selected cancers through shared angiogenic, inflammatory, and polygenic aging-related mechanisms.